Інструкція із застосування PLERIXAFOR EG
Зміст інструкції
PLERIXAFOR EG 20 mg/mL injectable solution
Generic medicine
Read this leaflet carefully before using this medicine as it contains important
information for you.
- Keep this leaflet. You may need to read it again.
- If you have any questions, ask your doctor.
- If any side effects occur, including those not listed in this leaflet, tell your doctor or nurse. See section 4.
Contents of this leaflet:
- 1. What Plerixafor EG is and what it is used for
- 2. What you need to know before you use Plerixafor EG
- 3. How to use Plerixafor EG
- 4. Possible side effects
- 5. How to store Plerixafor EG
- 6. Contents of the pack and other information
1. What is Plerixafor EG and what is it used for
Plerixafor EG contains the active substance plerixafor, which blocks a protein on the surface of blood stem cells.
This protein “binds” the blood stem cells to the bone marrow.
Plerixafor improves the release of stem cells into the bloodstream (mobilization). The stem cells
can then be collected using a machine that separates the components of the blood (apheresis machine) to be frozen and stored until transplantation.
If mobilization is poor, Plerixafor EG is used to promote the collection of stem cells in the
blood from the patient, for collection, storage and reintroduction (transplantation),
- in adults with lymphoma (a cancer of white blood cells) or multiple myeloma (a cancer that attacks plasma cells in the bone marrow);
- in children aged between 1 and less than 18 years with lymphoma or solid tumors.
2. What you need to know before using Plerixafor EG
Do not use Plerixafor EG
- if you are allergic to plerixafor or to any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Talk to your doctor before using Plerixafor EG.
Tell your doctor:
- if you have or have had heart problems;
- if you have kidney problems. Your doctor may adjust the dose;
- if you have a high number of white blood cells;
- if you have a low number of platelets;
- if you have previously experienced feelings of fainting or dizziness when standing up or sitting down, or if you have ever fainted during injections.
Your doctor may perform blood tests regularlyto check the number of your blood cells.
The use of Plerixafor EG for stem cell mobilization is not recommended if you suffer from
leukemia (a cancer of the blood or bone marrow).
Other medicines and Plerixafor EG
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Pregnancy and breastfeeding
Do not use Plerixafor EG if you are pregnant as there is no experience on the effects of Plerixafor EG
in pregnant women. It is important that you inform your doctor if you are pregnant, if you think
you may be pregnant or if you are planning a pregnancy. It is recommended to use a contraceptive method if you
are a woman of childbearing potential.
Do not breastfeed while using Plerixafor EG, as it is not known whether Plerixafor EG is excreted in breast
milk.
Driving and using machines
Plerixafor EG can cause dizziness and fatigue. Therefore, you should not drive if you feel unwell, tired or dizzy.
Plerixafor EG contains sodium
This medicine contains less than 1 mmol (23 mg) of sodium per dose, i.e. essentially ‘sodium-free’.
3. How to use Plerixafor EG
The medication will be injected by a doctor or a nurse.
You will first receive G-CSF, then you will be administered Plerixafor EG.
Mobilization will be initiated by administering you another medication called G-CSF (granulocyte colony-stimulating factor). The G-CSF will promote the correct action of Plerixafor EG in your body.
How much Plerixafor EG is administered?
The recommended dose of Plerixafor EG for adults is 20 mg (fixed dose) or 0.24 mg/kg of body weight per day. The recommended dose for children between 1 and less than 18 years of age is 0.24
mg/kg of body weight/day.
The dose will therefore depend on your body weight, which must be measured the week before you receive your
first dose. If you have moderate or severe kidney problems, your doctor will reduce the dose.
How is Plerixafor EG administered?
Plerixafor EG is administered by subcutaneous injection (under the skin).
When is Plerixafor EG administered for the first time?
You will receive your first dose 6 to 11 hours before apheresis (the collection of your blood stem cells).
For how long will you be administered Plerixafor EG?
Treatment lasts for 2 to 4 consecutive days (in some cases up to 7 days), until a sufficient amount of stem cells has been
collected for transplantation. In limited cases, not enough stem cells may be collected, so the collection attempt will be interrupted.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
manifest.
Tell your doctor immediately if
- shortly after receiving Plerixafor EG, you develop skin rash, swelling around the eyes, shortness of breath or lack of oxygen, a feeling of dizziness when standing up or sitting down, a feeling of fainting or fainting;
- if you have pain in the upper left side of your abdomen (stomach) or in your left shoulder.
Very common side effects (may affect more than 1 in 10 people)
- diarrhoea, nausea (feeling sick), redness or irritation at the injection site;
- low red blood cell count in laboratory tests (anaemia in children).
Common side effects (may affect up to 1 in 10 people)
- headache;
- dizziness, feeling tired or unwell;
- difficulty sleeping;
- flatulence, constipation, indigestion, vomiting;
- gastric symptoms such as pain, bloating or discomfort;
- dry mouth, numbness around the mouth;
- sweating, general redness of the skin, joint pain, muscle and bone pain.
Uncommon side effects (may affect up to 1 in 100 people)
- allergic reactions such as skin rash, swelling around the eyes, shortness of breath;
- anaphylactic reactions, including anaphylactic shock;
- abnormal dreams, nightmares.
Rarely, gastrointestinal side effects can be serious (diarrhoea, vomiting, stomach pain
and nausea).
Heart attacks
In clinical studies, patients with risk factors for a heart attack have experienced, with uncommon frequency
heart attacks after receiving plerixafor and G-CSF. Tell your doctor immediately
if you experience chest discomfort.
Tingling and numbness
Tingling and numbness are common in patients treated for cancer. About one in five
patients experience these sensations. However, these effects do not appear to occur more frequently
when taking Plerixafor EG.
Blood tests may show an increase in white blood cell count (leukocytes).
Reporting of side effects
If you get any side effects, talk to your doctor or nurse. You can also report side effects directly
through the national reporting system at https://www.aifa.gov.it/content/segnalazioni-
reazioni-avverse. By reporting side effects you can help provide more information on the
safety of this medicine.
5. How to store Plerixafor EG
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the pack and on the vial.
This medicine does not require any special storage conditions.
After opening the vial, Plerixafor EG must be used immediately.
Do not dispose of any medicine in waste water or household waste. Ask your pharmacist how to dispose of
medicines you no longer use. This will help protect the environment.
6. Contents of the pack and other information
What Plerixafor EG contains
- The active substance is plerixafor. Each mL of injectable solution contains 20 mg of plerixafor. Each vial contains 24 mg of plerixafor in a 1.2 mL solution.
- The other ingredients are: sodium chloride, hydrochloric acid (concentrated) and sodium hydroxide for pH adjustment and water for injections.
Description of the appearance of Plerixafor EG and contents of the pack
Plerixafor EG presents as a clear, colorless to pale yellow injectable solution within a
transparent Type I Fiolax glass vial closed with a chlorobutyl/butyl fluorotec stopper, sealed
with an aluminum/polypropylene flip-off cap. Each vial contains 1.2 mL of solution.
Each pack contains 1 vial.
Marketing Authorisation Holder
EG S.p.A., via Pavia 6, 20136 Milano, Italy
Manufacturer
Pharmadox Healthcare Limited, KW20A, Kordin Industrial Park, Paola PLA 3000 - Malta
This medicinal product is authorised in the Member States of the European Economic Area under the following
names:
AT Plerixafor STADA 20 mg/ml Injektionslösung
DE Plerixafor STADA 20 mg/ml Injektionslösung
ES Plerixafor STADA 20 mg/ml solución inyectable EFG
FR Plerixafor EG 20 mg/ml, solution injectable
IT Plerixafor EG

- Країна реєстрації
- Лікарська формаInjectable solution, 20 MG/ML
- Код АТХL03AX16
- Діюча речовина
- Потрібен рецептТак
- Виробник
- Ця інформація надана лише для ознайомлення і не є медичною порадою. Рішення щодо лікування завжди приймає лікар.
- Альтернативи до PLERIXAFOR EGЛікарська форма: Injectable solution, 20 MG/MLДіюча речовина: ПлериксафорВиробник: SANOFI B.V.Потрібен рецептЛікарська форма: Injectable solution, 20 mg/mlДіюча речовина: ПлериксафорВиробник: ACCORD HEALTHCARE, S.L.U.Потрібен рецептЛікарська форма: Injectable solution, 20 MG/MLДіюча речовина: ПлериксафорВиробник: TILLOMED ITALIA SRLПотрібен рецепт
Аналоги PLERIXAFOR EG в інших країнах
Препарати з тією самою діючою речовиною, доступні в інших країнах.
Аналог PLERIXAFOR EG у Іспанія
Аналог PLERIXAFOR EG у Польща
Аналог PLERIXAFOR EG у Україна
Лікарі онлайн щодо PLERIXAFOR EG
Застосування, безпека та можливість призначення рецепта — за результатами медичної оцінки.
Отримайте рецепт на PLERIXAFOR EG онлайн
Заповніть форму за 2 хвилини
Розкажіть про симптоми, історію хвороби та потрібний препарат.
Оберіть лікаря або ми призначимо
Оберіть спеціаліста або ми підберемо найближчого доступного лікаря.
Лікар розглядає ваш випадок
Зазвичай протягом 30 хвилин. Може ставити уточнювальні запитання в чаті.
Отримайте в будь-якій аптеці
Електронний рецепт надсилається на вашу пошту — дійсний по всій Польщі.
Часті запитання
PLERIXAFOR EG потребує рецепта в Італія. Ви можете обговорити з лікарем онлайн, чи підходить цей лікарський засіб для вашої ситуації.
Діюча речовина у PLERIXAFOR EG — Плериксафор. Це допомагає визначити препарати з тим самим складом, але під іншими торговими назвами.
PLERIXAFOR EG виробляється компанією EG S.P.A.. Назва бренду та упаковка можуть відрізнятися залежно від дистрибʼютора.
Лікарі, зокрема Сімейні лікарі, Психіатри, Дерматологи, Кардіологи, Ендокринологи, Гастроентерологи, Пульмонологи, Нефрологи, Ревматологи, Гематологи, Інфекціоністи, Алергологи, Геріатри, Педіатри, Онкологи, можуть оцінити доцільність застосування PLERIXAFOR EG з урахуванням вашого стану та місцевих правил. Ви можете записатися на онлайн-консультацію, щоб обговорити симптоми та можливі подальші кроки.
Польща має добре розвинену систему охорони здоров'я у великих містах, таких як Варшава, Краків, Вроцлав і Гданськ. Аптеки широко доступні та працюють відповідно до чинного законодавства, забезпечуючи доступ до рецептурних препаратів.
Ви можете придбати PLERIXAFOR EG у Варшаві, Кракові, Вроцлаві або Гданську в будь-якій аптеці за наявності дійсного рецепта.
Щоб отримати рецепт, ви можете скористатися Oladoctor:
Інші препарати з тією самою діючою речовиною (Плериксафор) включають MOTSOBIL, PLERIXAFOR AKKORD, PLERIXAFOR TILLOMED. Вони можуть відрізнятися торговою назвою або формою випуску, але містять той самий терапевтичний компонент. Перед зміною або початком прийому нового препарату варто проконсультуватися з лікарем.
















